Journal profile · MEDICINE, RESEARCH & EXPERIMENTAL
MedComm
ISSN 2688-2663 · Wiley · Australia · Quarterly · Founded 2020
MedComm: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 14.1 (journal website); fully open access; APC about USD 3,850; median 270 days to acceptance (136 articles, last 24 months); acceptance rate 16% (journal website); 533 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
MedComm is published by Wiley and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immune cells in cancer and RNA modifications and cancer, together about 21.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Aim of the journal MedComm is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance to human health. The journal emphasizes original findings that advance the understanding of pathogenesis or improve the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged. Scope and topics (including keywords) Indexing MedComm is interested in topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology and artificial intelligence. The journal focuses on clinical and experimental advances on disease characteristics, pathogenic mechanism and medical techniques. Topics of interest include, but are not limited to: Epigenetics, genomics, proteomics and metabonomics Non-coding RNA in disease Cell senescence and cell death Cellular signal transduction Gene therapy and gene editing Cancer immunology and immunotherapy Structural biology, chemical genomics and drug discovery High-definition imaging Artificial intelligence in medicine Stem cells and regenerative medicine Nanomedicine and drug delivery system Early disease diagnosis and biomarkers Clinical trials evaluating new treatments for cancer or other diseases Indexing Information: Biological Abstracts (Clarivate Analytics) BIOSIS Previews (Clarivate Analytics) Directory of Open Access Journals (DOAJ) Emerging Sources Citation Index (Clarivate Analytics) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) OneFile: Health and Medicine (GALE Cengage) OneFile: Nursing and Allied Health (GALE Cengage) ProQuest Central (ProQuest) PubMed (NLM) SCOPUS (Elsevier) Web of Science (Clarivate Analytics) MedComm
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTAL
Editor-in-chief James Henderson NaismithPublisher website
Editorial board by country: 19 in mainland China (about 25%); most named Mainland China 19, United States 17, Germany 6, United Kingdom 5, Japan 4 (75 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8%
- Immune cells in cancerImmunology and Microbiology6.9%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology6.7%
- SARS-CoV-2 and COVID-19 ResearchMedicine5.7%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.7%
- Ferroptosis and cancer prognosisMedicine4.7%
- Immune Cell Function and InteractionImmunology and Microbiology4.6%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 14.1Publisher website ·
- Impact factor (publisher) 2025
- 14.1Publisher website ·
- CiteScore 2026-06
- 12.5LetPub ·
- CiteScore (publisher)
- 12.5Publisher website ·
- CiteScore (publisher) 2025
- 12.5Publisher website ·
- SJR 2026-06
- 2.93LetPub ·
- SNIP 2026-06
- 2.04LetPub ·
- h-index
- 81OpenAlex ·
- i10-index
- 642OpenAlex ·
- 2-year mean citedness
- 10.82OpenAlex ·
- Self-citation rate
- 2.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 438LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 470Publisher website ·
- Downloads per year (publisher) 2025
- 1,451,211Publisher website ·
Articles by year OpenAlex count · 1,823 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 459 | 459 | 534 |
| 2025 | 533 | 533 | 6,126 |
| 2024 | 366 | 366 | 8,035 |
| 2023 | 258 | 258 | 9,801 |
| 2022 | 93 | 93 | 4,566 |
| 2021 | 65 | 65 | 3,345 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
270 daysMedian, submission to acceptance · P25–P75 216 days – 350 days
- Acceptance to online
- median 38 days (138 articles)
- Submission to online
- median 313 days
- Sample
- 136 articles with submission and acceptance dates (1,029 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Acceptance rate (publisher)
- 16%Publisher website ·
- Acceptance rate (publisher) 2025
- 16%Publisher website ·
- Submission to first decision
- 21 daysPublisher website ·
- Submission to first decision 2025
- 21 daysPublisher website ·
- Submission to acceptance 2025
- 251 daysPublisher website ·
- Acceptance to publication 2025
- 37 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,850 / GBP 2,810 / EUR 3,360 | Yes | CC BY | |
| OpenAlex | USD 3,500 / EUR 3,050 / GBP 2,550 | — | — | |
| LetPub | USD 3,500 / GBP 2,550 / EUR 3,050 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
Other charges and waivers (author guidelines)
- Submission fee
- Charged; see the journal's website for the amount
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- 3–6
- Manuscript length
- ≤ 6,000 words
- Reference style
- Chicago
- First submission
- Free format: the journal's layout is not required
- Highlights
- Required
- Graphical abstract
- Required
Article types accepted12, with length limits
- editorialOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 1,000 words
- editorialsEditorials are the most important statement and opinions of global opinion leaders in relevant specialties and specially invited by the Editor, but unsolicited …Length not stated
- highlightHighlight aims to point the MedComm readership to the latest novel findings published in other high-impact journals.Length not stated
- letterOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 1,200 words
- opinionOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
- original articleOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
- perspectiveOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 3,000 words
- perspectivesPerspectives discuss published findings and ideas from a personal viewpoint.Length not stated
- research articleOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…main text ≤ 6,000 words
- reviewOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
- systematic reviewOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
- viewpointOriginal article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make signi…Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, License & copyright, Peer review, Preprints
- Authorship Authorship
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest Statement
Authors will be asked to provide a conflict of interest statement during the submission process. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Pot…
Source ↗Publisher website ·- Data availability Data Sharing and Data Accessibility
Please review Wiley’s policy here. This journal encourages data sharing.
Source ↗Publisher website ·- License & copyright
Open access under CC BY license; author retains copyright Model summary
Accepted papers will be published under CC BY - Creative Commons Attribution License. With the Creative Commons license, the author retains copyright and the public is allowed to reuse the content.
Source ↗Publisher website ·- Peer review Peer Review and Acceptance
Single-blind peer review by two reviewers Model summary
The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer reviewed by two reviewers. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.
Source ↗Publisher website ·- Preprints
Preprint policy: accepts articles previously published on preprint servers Model summary
This journal accepts article previously published on preprint servers. MedComm will consider for review articles previously available as preprints.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley
- Country or region
- Australia
- Language
- English
- Frequency
- Quarterly
- Founded
- 2020
- ISSN
- 2688-2663
- Society / sponsor
- Sichuan International Medical Exchange & Promotion Association
- Latest issue on the website
- Volume 7, Issue 10 (October 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about MedComm
What CAS zone is MedComm in?
In the 2025 upgraded edition of the CAS Journal Ranking, MedComm is in Zone 1 of Medicine, and in Zone 1 of the minor category Medicine, Research & Experimental; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of MedComm?
The journal's website gives an impact factor of 14.1 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 12.5, h-index 81.
How long does peer review take at MedComm?
Based on the dates recorded on 136 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 270 days (interquartile range 216–350 days); authors report an average review time of about 10 weeks; the journal's website gives an acceptance rate of 16% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of MedComm?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: 3–6; Manuscript length: ≤ 6,000 words; Reference style: Chicago; First submission: Free format: the journal's layout is not required; Highlights: Required; Graphical abstract: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of MedComm based?
Of the 75 board members whose country the journal's board page names, 19 (about 25%) are in mainland China; the countries named most often are Mainland China (19), United States (17) and Germany (6). Counted from the institutions listed on the board page; for reference only.
Which databases index MedComm?
According to LetPub and DOAJ records, MedComm is indexed in ESCI, Scopus and DOAJ.
Is MedComm open access, and what is the APC?
MedComm is a fully open-access journal. APC about USD 3,850.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .